P3-071: Respiratory symptoms improvement in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib: Quality of Life analysis of the IFCT-0401 trial  by Morin, Franck et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS708
National Cancer Institute has granted a 2-year multicentric prospective 
project entitled: Evaluation of the EGFR Mutation status for the admin-
istration of EGFR-TKIs in non small cell lung Carcinoma (ERMETIC). 
ERMETIC was constituted by 15 regional centers in France, among 
which an expert pathologists panel was formed, and an external refer-
ence molecular laboratory. ERMETIC has several consecutive objec-
tives, but the ﬁrst was to evaluate the ability of each center to perform 
biomarker assays in parafﬁn embedded tissues and the concordance of 
their results between centers, with the expert pathologists panel and an 
external molecular reference laboratory.
Methods: A tumor bank was composed by centrally collected speci-
mens from non-previously treated patients that underwent surgery. It 
was enriched by specimens harboring EGFR-mutation or obtained from 
non-smokers (NS) and females (F) with adenocarcinoma (ADC). The 
bank consisted of snap frozen and parafﬁn embedded tissues, as well as 
DNA extracts. All specimens were send blinded to the different centers 
for molecular analysis. EGFR IHC and FISH were performed by the 
3 panel pathologists on the entire tumor bank. EGFR and K-ras genes 
were sequenced by centers on their own specimens as well as on the 
DNA extracts of the entire bank, and by the molecular reference labora-
tory on all the DNA samples but also on the snap frozen specimens. 
Concordance results are presented by the percentage of discordant 
results, and by kappa coefﬁcients for observer agreement, together with 
95% conﬁdence intervals. 
Results: The tumor bank contained specimens from 74 surgically 
resected NSCLC of which 16% with known EGFR-mutation and 74% 
with ADC histology. 76% of patients were F and 49% NS. At the time 
of the abstract submission, all EGFR IHC and FISH analyses and 
EGFR and K-ras mutation sequences have been completed. Deﬁnitive 
concordance results will be presented at the IASLC meeting. 
Conclusions: The ability to study EGFR-TKIs predictive biomarkers 
of efﬁcacy in parafﬁn embedded tumor specimens by routine labora-
tories and their capacity to give concordant results are a prerequisite 
to the implementation of these techniques in the clinical practice in 
France.
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Background: A multicenter single-arm Phase II study evaluated the ef-
ﬁcacy, safety, and tolerability of geﬁtinib (250 mg/dy) in patients with 
non-resectable ADC-BAC. A second objective was to assess respiratory 
symptoms and quality of life (QOL) improvements and their relation-
ship to disease control (DC) and objective response (OR). 
Methods: Patients received oxygen saturation measurement (SaO2), as 
well as Respiratory Symptoms Scale (RSS) evaluation and QOL assess-
ment by Saint George’s Respiratory Questionnaire (SGRQ), at baseline, 
1 month (M1), 3 months (M3) and every 3 months until progression. 
SaO2 was determined by pulse digital oxymetry. For RSS, patients 
answered each item (cough, dyspnea, wheeze, chest tightness, sputum 
production and nocturnal awakening) on a six-point scale ranging 
from 0 (none) to 4 (constant). One missing point invalidates the whole 
questionnaire. Overall function scores (0-24) were calculated, with 
lower scores reﬂecting better function and symptom response. SGRQ is 
a standardized self-administered airways disease-speciﬁc questionnaire 
divided into 3 subscales: symptoms (8 items), activity (16 items) and 
impacts (26 items). For each subscale and for the overall questionnaire, 
scores range from 0 to 100 (maximum impairment). Results of SaO2, 
RSS and SGRQ (total score) were compared at each endpoint for the 
overall population and by response categories (p value obtaining by 
paired t-test).
Results: DC rate and OR at 3 months were 29.3% and 12.9%, re-
spectively, in the 85/88 evaluable patients. The table below shows: 
(1) compliance and results of SaO2, RSS and SGRQ at baseline; (2) 
comparisons between times of evaluation (M1 or M3) and by response 
categories. Compliance with QOL was similar for SaO2, RSS and 
SGRQ and similarly decreased with time in all response categories. At 
M0, there is no statistically signiﬁcant difference of baseline results 
between response groups and the overall population. At 1 month, SaO2, 
RSS and SGRQ signiﬁcantly improved in controlled and responding 
patients, but did not improve between M1 and M3 (M3-M1, data not 
shown). Although these parameters did not deteriorate at M1 in pro-
gressors, they signiﬁcantly deteriorated at M3. 
Conclusions: These results show that: (1) QOL improvement may 
precede objective response observed with geﬁtinib and (2) absence of 
1-month QOL improvement is associated with progression at M3 (or 
before). These suggests that QOL should be an interesting surrogate 
marker of efﬁcacy as objective response is difﬁcult to assess in ADC-
BAC. Finally, because SGRQ is time consuming for patients as well 
as for analyses and progressions are mostly within the lungs, ongoing 
IFCT trials on this tumour will preferably use SaO2 and RSS for QOL 
evaluation. 
Characteristics M0 
% Mean p value
M1-M0
MD RMD % p value
M3-M0
MD RMD % p value
All (n=85)
SaO2 95 92.69 - -0.04 -0.04 NS 0.78 1.80 NS
RSS 94 9.18 - -1.06 -11.37 0.013 -0.83 -10.58 NS
SGRQ 94 42.19 - -1.38 -3.31 NS -1.78 -5.25 NS
OR (n=11)
SaO2 91 90.00 0.22 6.32 7.02 0.037 8.68 8.80 0.035
RSS 91 8.30 0.62 -6.00 -62.34 0.012 -5.57 -54.17 0.046
SGRQ 91 43.75 0.84 -18.11 -39.08 0.025 -21.12 -45.58 0.010
DCR (n=25)
SaO2 92 92.26 0.77 3.41 3.71 0.023 4.19 4.62 0.037
RSS 96 6.92 0.07 -3.21 -42.66 0.008 -2.47 -32.41 0.038
SGRQ 96 39.45 0.62 -9.78 -25.03 0.007 -11.40 -29.17 0.004
PROG (n=60)
SaO2 93 92.84 0.88 -1.43 -1.54 0.038 -2.84 -1.08 0.039
RSS 93 10.14 0.29 -0.25 -2.56 NS 1.13 13.95 NS
SGRQ 93 43.36 0.78 1.92 4.51 NS 9.53 34.02 0.044
%: compliance of paired QOL was expressed as % of expected
MD: Mean diﬀerence; RMD %: Relative Mean diﬀerence %
